

PACKAGE INSERT TEMPLATE FOR LORATADINE TABLET & LORATADINE SYRUP

Brand or Product Name

[Product name] Tablet 10mg
[Product name] Syrup 1mg/ml

Name and Strength of Active Substance(s)

Loratadine 10mg
Loratadine 1mg/ml

Product Description

*[Visual description of the appearance of the product (eg colour, marking, flavour etc) eg
Tablet - White, circular flat beveled edge tablets marked '100' on one side
Syrup - Clear, colourless syrup]*

Pharmacodynamics

Loratadine, the active ingredient is a tricyclic antihistamine with selective, peripheral H₁-receptor activity. Loratadine has no clinically significant sedative or anticholinergic properties in the majority of the population and when used at the recommended dosage. During long-term treatment there were no clinically significant changes in vital signs, laboratory test values, physical examinations or electrocardiograms. Loratadine has no significant H₂-receptor activity. It does not inhibit norepinephrine uptake and has practically no influence on cardiovascular function or on intrinsic cardiac pacemaker activity.

Pharmacokinetics

After oral administration, loratadine is rapidly and well absorbed and undergoes an extensive first pass metabolism, mainly by CYP3A4 and CYP2D6. The major metabolite-desloratadine (DL) - is pharmacologically active and responsible for a large part of the clinical effect. Loratadine and DL achieve maximum plasma concentrations (T_{max}) between 1–1.5 hours and 1.5–3.7 hours after administration, respectively.

Increase in plasma concentrations of loratadine has been reported after concomitant use with ketoconazole, erythromycin, and cimetidine in controlled trials, but without clinically significant changes (including electrocardiographic).

Updated August 2011

Loratadine is highly bound (97 % to 99 %) and its active metabolite moderately bound (73 % to 76 %) to plasma proteins.

In healthy subjects, plasma distribution half-lives of loratadine and its active metabolite are approximately 1 and 2 hours, respectively. The mean elimination half-lives in healthy adult subjects were 8.4 hours (range = 3 to 20 hours) for loratadine and 28 hours (range = 8.8 to 92 hours) for the major active metabolite.

Approximately 40 % of the dose is excreted in the urine and 42 % in the faeces over a 10 day period and mainly in the form of conjugated metabolites. Approximately 27 % of the dose is eliminated in the urine during the first 24 hours. Less than 1 % of the active substance is excreted unchanged in active form, as loratadine or DL.

The bioavailability parameters of loratadine and of the active metabolite are dose proportional. The pharmacokinetic profile of loratadine and its metabolites is comparable in healthy adult volunteers and in healthy geriatric volunteers.

Concomitant ingestion of food can delay slightly the absorption of loratadine but without influencing the clinical effect.

In patients with chronic renal impairment, both the AUC and peak plasma levels (C_{max}) increased for loratadine and its metabolite as compared to the AUCs and peak plasma levels (C_{max}) of patients with normal renal function. The mean elimination half-lives of loratadine and its metabolite were not significantly different from that observed in normal subjects. Haemodialysis does not have an effect on the pharmacokinetics of loratadine or its active metabolite in subjects with chronic renal impairment.

In patients with chronic alcoholic liver disease, the AUC and peak plasma levels (C_{max}) of loratadine were double while the pharmacokinetic profile of the active metabolite was not significantly changed from that in patients with normal liver function. The elimination half-lives for loratadine and its metabolite were 24 hours and 37 hours, respectively, and increased with increasing severity of liver disease.

Loratadine and its active metabolite are excreted in the breast milk of lactating women.

Indication

Loratadine is indicated for the relief of symptoms associated with allergic rhinitis, such as sneezing, nasal discharge (rhinorrhea) and itching, as well as ocular itching and burning. Nasal and ocular signs and symptoms are relieved rapidly after oral administration.

Updated August 2011

Loratadine is also indicated for relief of symptoms and signs of chronic urticaria and other allergic dermatologic disorders.

Recommended Dosage

Adults and Children 12 years of age and over

Loratadine Tablet: One tablet (10 mg) once daily;
Loratadine Syrup: Two 5 ml spoonfuls (10 mg) once daily.

Children 6 to 12 years of age

Loratadine Tablet or Loratadine Syrup:
Body Weight >30 kg -- One tablet (10 mg) once daily or two 5 ml spoonfuls (10 mg) syrup once daily.
Body Weight <30 kg -- One 5 ml spoonful (5 mg) syrup once daily.

Children 2 to 6 years of age:

Loratadine Syrup:
Body Weight >30 kg -- Two 5 ml spoonfuls (10 mg) syrup once daily.
Body Weight <30 kg -- One 5 ml spoonful (5 mg) syrup once daily.

Safety and efficacy of Loratadine has not been established in children younger than 2 years of age. Patients with severe liver impairment should be administered a lower initial dose because they may have reduced clearance of loratadine; an initial dose of 5 mg or 5 ml once daily, or 10 mg or 10 ml every other day is recommended.

Mode of Administration

Oral

Contraindications

Loratadine is contraindicated in patients who are hypersensitivity to the active substance or to any of the excipients in these formulations.

Warnings and Precautions

Loratadine should be administered with caution in patients with severe liver impairment. The administration of Loratadine Products should be discontinued at least 48 hours before skin tests since antihistamines may prevent or reduce otherwise positive reactions to dermal reactivity index.

Updated August 2011

[Specific package insert requirement for loratadine]

Warning :

Drugs known to inhibit hepatic metabolism should be coadministered with caution until definitive interaction studies can be completed. The number of subjects who concomitantly received macrolide antibiotics, ketoconazole, cimetidine, ranitidine, or theophylline along with loratadine in controlled clinical trials is too small to rule out possible drug interactions.

Effects on ability to drive and use machines

No impairment occurred in patients receiving loratadine. However, patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines.

Interactions with Other Medicaments

When administered concomitantly with alcohol, loratadine has no potentiating effects as measured by psychomotor performance studies. Potential interaction may occur with all known inhibitors of CYP3A4 or CYP2D6 resulting in elevated levels of loratadine which may cause an increase in adverse events.

Statement on Usage During Pregnancy and Lactation

Safe use of loratadine during pregnancy has not been established; therefore, use only if the potential benefit justifies the potential risk to fetus. Since loratadine is excreted in breast milk, a decision should be made whether to discontinue nursing or discontinue the drug.

Adverse Effects / Undesirable Effects

In paediatric population, children aged 2 through 12 years, common adverse reactions reported in excess of placebo were headache, nervousness and fatigue.

The most frequent adverse reactions in adults and adolescents were somnolence, headache, increased appetite and insomnia. Other adverse reactions reported very rarely during the post-marketing period are listed below.

Updated August 2011

Immune system disorders

Anaphylaxis

Nervous system disorders

Dizziness

Cardiac disorders

Tachycardia, palpitation

Gastrointestinal disorders

Nausea, dry mouth, gastritis

Hepatobiliary disorders

Abnormal hepatic function

Skin and subcutaneous tissue disorders

Rash, alopecia

General disorders and administration site conditions

Fatigue

Overdose and Treatment

Overdosage with loratadine increase the occurrence of anticholinergic symptoms. Somnolence, tachycardia and headache have been reported with overdoses. In the event of overdose, general symptomatic and supportive measures are to be instituted and maintained for as long as necessary. Administration of activated charcoal as a slurry with water may be attempted. Gastric lavage may be considered. Loratadine is not removed by haemodialysis and it is not known if loratadine is removed by peritoneal dialysis. Medical monitoring of the patient is to be continued after emergency treatment.

Storage Conditions

Store below°C

Dosage Forms and Packaging Available

[Packaging type & pack size eg

Tablet - Alu-alu blister of 10s X 10/box, HDPE bottle of 30s/box

Syrup – PET plastic bottle of 60ml/box]

Name and Address of Manufacturer

[Name & full address of manufacturer]

Updated August 2011

Name and Address of Marketing Authorization Holder
[Name & full address of marketing authorization holder]

Date of Revision of Package Insert
[day/month/year]